News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

VIALE-A Trial: Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
(Partial video transcript; please use link to view video or complete transcript) Daniel Pollyea, MD, MS: The VIALE-A trial was a landmark confirmatory study mandated by the FDA for full approval of venetoclax. It was a randomized study that enrolled newly diagnosed patients with…

ASTEX PHARMACEUTICALS PRESENTS OVERALL SURVIVAL DATA FROM ASCERTAIN PHASE 3 STUDY OF ORAL HYPOMETHYLATING AGENT INQOVI® (DECITABINE AND CEDAZURIDINE) IN MDS AND CMML AT INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES

Original Publication Date
Article Source
External Web Content
Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form…

Researchers discover potential Achilles heel of pediatric acute myeloid leukemia

Original Publication Date
Article Source
External Web Content
Researchers at Baylor College of Medicine and Texas Children's Hospital have uncovered a potential Achilles heel of acute myeloid leukemia (AML) in children that could lead to new treatments for this devastating disease. The team was the first to identify specific super-enhancers…

FDA Approves Ruxolitinib in Chronic Graft-Versus-Host Disease

Original Publication Date
Article Source
External Web Content
The FDA has approved ruxolitinib (Jakafi) for the treatment of patients 12 years and older with chronic graft-versus-host disease (GvHD) after failure of 1 or 2 lines of systemic therapy, according to a press release by Incyte. The approval is based on data from the REACH3 trial…

Life Expectancy Still Lower for Blood or Marrow Transplant Recipients

Original Publication Date
Article Source
External Web Content
While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study found. Compared with the general…

FDA approves belumosudil for chronic graft-versus-host disease

Original Publication Date
Article Source
External Web Content
On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families